S&P 500   5,100.95 (+0.09%)
DOW   38,959.26 (-0.10%)
QQQ   439.60 (+0.14%)
AAPL   179.53 (-0.67%)
MSFT   412.76 (-0.21%)
META   489.50 (-0.13%)
GOOGL   138.28 (-0.13%)
AMZN   176.60 (-0.09%)
TSLA   201.05 (-0.41%)
NVDA   800.19 (+1.15%)
NIO   5.82 (+1.22%)
AMD   198.30 (+3.00%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
F   12.48 (+0.32%)
MU   91.50 (+0.98%)
CGC   3.32 (+0.91%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
PFE   26.68 (+0.45%)
PYPL   60.55 (+0.35%)
XOM   105.40 (+0.84%)
S&P 500   5,100.95 (+0.09%)
DOW   38,959.26 (-0.10%)
QQQ   439.60 (+0.14%)
AAPL   179.53 (-0.67%)
MSFT   412.76 (-0.21%)
META   489.50 (-0.13%)
GOOGL   138.28 (-0.13%)
AMZN   176.60 (-0.09%)
TSLA   201.05 (-0.41%)
NVDA   800.19 (+1.15%)
NIO   5.82 (+1.22%)
AMD   198.30 (+3.00%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
F   12.48 (+0.32%)
MU   91.50 (+0.98%)
CGC   3.32 (+0.91%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
PFE   26.68 (+0.45%)
PYPL   60.55 (+0.35%)
XOM   105.40 (+0.84%)
S&P 500   5,100.95 (+0.09%)
DOW   38,959.26 (-0.10%)
QQQ   439.60 (+0.14%)
AAPL   179.53 (-0.67%)
MSFT   412.76 (-0.21%)
META   489.50 (-0.13%)
GOOGL   138.28 (-0.13%)
AMZN   176.60 (-0.09%)
TSLA   201.05 (-0.41%)
NVDA   800.19 (+1.15%)
NIO   5.82 (+1.22%)
AMD   198.30 (+3.00%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
F   12.48 (+0.32%)
MU   91.50 (+0.98%)
CGC   3.32 (+0.91%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
PFE   26.68 (+0.45%)
PYPL   60.55 (+0.35%)
XOM   105.40 (+0.84%)
S&P 500   5,100.95 (+0.09%)
DOW   38,959.26 (-0.10%)
QQQ   439.60 (+0.14%)
AAPL   179.53 (-0.67%)
MSFT   412.76 (-0.21%)
META   489.50 (-0.13%)
GOOGL   138.28 (-0.13%)
AMZN   176.60 (-0.09%)
TSLA   201.05 (-0.41%)
NVDA   800.19 (+1.15%)
NIO   5.82 (+1.22%)
AMD   198.30 (+3.00%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
F   12.48 (+0.32%)
MU   91.50 (+0.98%)
CGC   3.32 (+0.91%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
PFE   26.68 (+0.45%)
PYPL   60.55 (+0.35%)
XOM   105.40 (+0.84%)

Pacira BioSciences (PCRX) Stock Forecast & Price Target

$29.72
-0.19 (-0.64%)
(As of 02/29/2024 ET)

Pacira BioSciences Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$51.44
73.10% Upside
High Forecast$58.00
Average Forecast$51.44
Low Forecast$42.00
TypeCurrent Forecast
3/2/23 to 3/1/24
1 Month Ago
1/31/23 to 1/31/24
3 Months Ago
12/2/22 to 12/2/23
1 Year Ago
3/2/22 to 3/2/23
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$51.44$51.44$52.36$62.80
Predicted Upside73.10% Upside59.66% Upside51.99% Upside43.48% Upside
Get Pacira BioSciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.


PCRX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PCRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pacira BioSciences Stock vs. The Competition

TypePacira BioSciencesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside73.10% Upside1,857.28% Upside7.23% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/1/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$45.00+51.41%
2/8/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$57.00+100.07%
12/20/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$42.00+33.46%
11/6/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$63.00 ➝ $57.00+83.63%
11/3/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$50.00 ➝ $42.00+35.31%
11/3/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$67.00 ➝ $58.00+86.92%
10/23/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$60.00 ➝ $57.00+99.72%
8/3/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$60.00 ➝ $55.00+49.82%
8/3/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$50.00+36.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:39 AM ET.












PCRX Price Target - Frequently Asked Questions

What is Pacira BioSciences's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Pacira BioSciences stock is Buy based on the current 9 buy ratings for PCRX. The average twelve-month price prediction for Pacira BioSciences is $51.44 with a high price target of $58.00 and a low price target of $42.00. Learn more on PCRX's analyst rating history.

Do Wall Street analysts like Pacira BioSciences more than its competitors?

Analysts like Pacira BioSciences more than other Medical companies. The consensus rating for Pacira BioSciences is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how PCRX compares to other companies.

Does Pacira BioSciences's stock price have much upside?

According to analysts, Pacira BioSciences's stock has a predicted upside of 62.60% based on their 12-month stock forecasts.

What analysts cover Pacira BioSciences?

Pacira BioSciences has been rated by Needham & Company LLC, Raymond James, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:PCRX) was last updated on 3/1/2024 by MarketBeat.com Staff